Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Udenafil in adolescents with single ventricle physiology after Fontan palliation
NCT03013751Phase 3Completed
- Sponsor
- Mezzion Pharma
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of udenafil in Single Ventricle Congenital Heart Disease (SVCHD), sponsored by Mezzion Pharma. Primary endpoint: Treatment-Emergent Adverse Events at 52 weeks. Started Feb 2017; status: completed.
02
Drugs
udenafil
03
Conditions
Single Ventricle Congenital Heart Disease (SVCHD)
Beyond the preview
Go deeper on NCT03013751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013751.